FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
On Nov. 15, 2026, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant)…